Jdt BBI still need to validate the manufacturing process according to AS. Also the small scale evaluation can throw up need for tweaking of the test. So whilst an rns signalling start of clinical validation could come monday it could equally not come till January. I am thinking this week is a distinct poss because we have had four weeks since the last rns for them to work on things.
CS tou make a good point. At tech transfer they have already frozen the design because, most likely, they are very satisfied with performance in small scale evaluation. That means they can say to manufacturers they have been chatting to 'hey look at these figures and the fact this is going to be clinically validated in 2 weeks for prof use and 4 weeks for home use. Sign up now and we can start tech transfer to you via BBI and you will be able to hit the ground running as validation completes.' Govmt might even permit them to reveal the demand confidentially for this purpose
Tricky. Its sensitivity that informs positive cases. I think they have enough innova supply til feb and then a domestic producer or producers can most likely take over.
I agree about the entry point. People say they made best test for zika but it was too late. Well zika was relatively short run and covid is not going to be. So what we are left with is Sir Al on his board, almost certainly with the best test nearly made, and hes about to catch the majority of a massive long wave.
Not like Brexit. The lower nasal version of lfd should be routine. They had already made significant progress 3 weeks ago. The remainder of the presale process will almost certainly complete within January, with interim update on the way.
I was keen on this a few month back when in double digits. For once my tortoise act worked out and got in at about 6. Was delighted with recent news and would lover another opportunity to pick up a bit more down at these levels. They might do badly or they very well might ten bag or more in next year or two.
What deeks is saying a out saliva is nothing especially new. Since the early days it was evident saliva was more challenging accuracy wise but it had the advantage of removing swabbing error. But the idea of combining both is very exciting.
Tom I've gone jury out on whether they have been commercial savvy and quick enough to adapt ( including with BAMS). And we have to take their time lines estimates with a pinch of salt. Nonetheless, no one has yet presented any convincing reason why they wont get tests to market by Jan or Feb and why these won't do really well given the quality of affimers. I am very bullish on the short, mid and long range need for testing and I think they will make multiples of mcap. First things first but I am pretty confident its going to ridiculously skew many holders portfolios by late summer.
There are several that are under a tenner a trade, eg ajbellyouinvest
Tom it may not be just hindsight. I mean if you know that there are technical difficulties don't rest your money generation strategy on overcoming them, esp. when you have another usp in the affimers themselves. So they should have done both from the start and then wed be sitting here talking about contracts and income. I am an outsider not a fly on the wall so maybe my premises are wrong. But so far with both this and BAMS they appear to have demonstrated commercial naivety in their approach.
Mart how long have you been ob this board? Long term holders know that hanging on a timeline word can lead to heartache. Ive done the formula myself:
Quickly = shortly but shortly + AS = longly = slowly.
Precision refers to a Avacta technology but is purely an ironic word when applied to AS timelines.